A New IVIG Just Got Approved. Here Is Why Your Insurance May Not Cover It Yet.
A New IVIG Just Got Approved. Here Is Why Your Insurance May Not Cover It Yet.
Abstract: The FDA approved Qivigy (immune globulin intravenous, human — kics 10%), a 10% IVIG formulation from Kedrion Biopharma, for adults with primary humoral immunodeficiency. While the approval expands the options available to people with life-threatening immune deficiencies, a predictable pattern follows every new IVIG product to market: formulary placement lags, step therapy requirements force brand substitutions, and Medicare Part B claims become complicated by temporary billing codes. Understanding this cycle before your doctor writes the prescription puts you in a much stronger position.
What Just Happened
Kedrion Biopharma received FDA approval for Qivigy, described in the agency's licensing documentation as immune globulin intravenous, human — kics 10%, for the treatment of primary humoral immunodeficiency (PHI) in adults.1 Qivigy is a 10% concentration intravenous formulation, meaning 100 mg of protein is delivered per 1 mL of solution — a concentration that shortens infusion time compared to older 5% formulations and reduces the total fluid volume you have to receive.
This approval arrives in a period of relative activity for the IVIG market. The FDA has licensed more than a dozen immune globulin products for intravenous or subcutaneous use since the first IVIG products were approved in the 1980s, and several new formulations have reached the U.S. market in the 2025-2026 period.2 Each new approval is genuinely meaningful for patients — different formulations carry different stabilizer ingredients, different maximum infusion rates, and different tolerability profiles that matter enormously when you are receiving infusions every three to four weeks for the rest of your life.3
What the Evidence Shows
Primary Humoral Immunodeficiency Is Not One Disease
The Immune Deficiency Foundation reports that more than 450 distinct primary immunodeficiency (PI) conditions have been identified, many involving impaired antibody production.4 The conditions that make patients most dependent on lifelong IVIG replacement therapy include:
Common Variable Immunodeficiency (CVID), the most frequently diagnosed symptomatic primary antibody deficiency, in which the immune system fails to produce adequate IgG, IgA, and often IgM. CVID typically presents in the second or third decade of life with recurrent sinus infections, pneumonias, and gastrointestinal infections. Delayed diagnosis averages four to seven years from symptom onset.4
X-linked Agammaglobulinemia (XLA), a condition affecting primarily males in which B cells fail to mature and virtually no immunoglobulin is produced. Without IVIG replacement, individuals with XLA face life-threatening bacterial infections beginning in infancy.4
Other antibody deficiencies, including specific antibody deficiency, hypogammaglobulinemia of uncertain significance, and combined immunodeficiencies with significant antibody component.
For all of these conditions, immunoglobulin replacement therapy is not optional. It is the standard of care and is lifelong in almost all cases. The Immune Deficiency Foundation states that the goal of Ig replacement therapy is to maintain IgG trough levels sufficient to prevent the frequency and severity of infections, with most immunologists targeting trough levels above 500 to 800 mg/dL depending on clinical response.3
Why Formulation Differences Matter
When your immune system cannot produce its own antibodies, the product you receive is your immune system. Tolerability differences across IVIG products are not trivial. The stabilizing agents used in different formulations — sucrose, glucose, maltose, glycine, and others — affect kidney safety, headache rates, and blood sugar impacts differently in different patients. Infusion rate limits vary by product. Volume requirements per dose differ based on concentration.
A 10% formulation like Qivigy delivers the same gram-equivalent dose in approximately half the fluid volume of a 5% formulation. For patients who experience volume-related side effects, or who receive high doses due to severe disease, that difference is clinically meaningful.3 When a physician prescribes a specific IVIG product by name, it reflects a clinical judgment about what that individual patient needs — not an arbitrary brand preference.
The Insurance Reality
The Formulary Placement Gap Is Predictable and Documented
Every time a new IVIG product receives FDA approval, the same insurance cycle plays out. Commercial health plans add new biologics to their formularies through a process that typically occurs once or twice per year during formal pharmacy and therapeutics (P&T) committee reviews. New products rarely make the first review cycle after approval. The practical result is that a newly approved IVIG product may not appear on any commercial formulary for six to eighteen months after FDA approval — meaning prior authorization requests will be denied simply because the product does not yet exist in the plan's system as an approved drug.5
Step Therapy Creates an Obstacle Even After Formulary Placement
Once a new IVIG product is on a formulary, it is typically placed on a non-preferred tier or subject to step therapy. Step therapy for IVIG means your insurer requires you to try and fail an "equivalent" product on the preferred list before approving the newer formulation. In practice, this means insurers may require documentation of intolerance to products like Gamunex-C, Privigen, or Gammagard before approving a newer option — even if your physician has a specific clinical reason to start you on the newer product from the beginning.5
This is especially frustrating for patients with documented side-effect histories with other IVIG products, patients initiating treatment for the first time, and patients who are being switched by a physician for sound clinical reasons. The step therapy requirement does not account for clinical nuance.
Medicare Part B: The Billing Code Problem
IVIG for primary humoral immunodeficiency is covered under Medicare Part B as a medical benefit, not Part D. This matters because Part B drugs are administered in a clinical setting and billed with HCPCS codes by the infusion center or physician office — not through a pharmacy benefit.6
When a new IVIG product receives FDA approval, it does not immediately receive a permanent HCPCS J-code. The Centers for Medicare and Medicaid Services processes new J-code applications on a semi-annual basis. Until a permanent code is assigned, providers may bill using temporary or unclassified codes, which can trigger manual review, payment delays, and administrative denials that have nothing to do with clinical appropriateness.6 Infusion centers and physician offices that are unfamiliar with the interim billing process may simply decline to dispense the new product until the permanent code is established.
The time from FDA approval to a permanent J-code can range from several months to more than a year, depending on CMS timelines and the product's application submission timing.
What This Means for You
If you have primary humoral immunodeficiency and your doctor wants to prescribe Qivigy specifically, you are entering a window where the administrative obstacles are at their highest. The drug is real, it is FDA approved, and it may be the right clinical choice for you. But the insurance infrastructure has not caught up yet.
This does not mean you cannot access it. It means you need to understand the process so you are not blindsided by a denial letter.
What You Can Do
1. Ask your doctor for a detailed letter of medical necessity. "Medical necessity" documentation for a specific IVIG formulation should explain why the particular product is warranted for you, including your diagnosis, prior treatment history, any adverse reactions to other formulations, and why this formulation is clinically appropriate. A letter that says "patient needs IVIG" will not be enough.
2. Confirm your plan's current formulary status for Qivigy before the prescription is submitted. Call the member services number on the back of your insurance card and ask specifically whether Qivigy (immune globulin intravenous, human — kics 10%) is on the current formulary, what tier it is on, and what prior authorization criteria apply. If the plan representative is unfamiliar with the product, ask to be connected to pharmacy benefit services.
3. If you receive a denial, identify the exact denial reason. Denials for new IVIG products commonly cite "formulary alternative available," "step therapy not met," or "product not covered." Each denial reason has a specific appeal pathway. "Formulary alternative available" can be challenged with a non-formulary exception if your physician documents why the formulary alternative is not appropriate for you.
4. If you have Medicare Part B, verify that your infusion center is familiar with the current billing code for Qivigy. During the period before a permanent J-code is assigned, the infusion site should work with Kedrion's patient access team or a specialty pharmacy to understand the correct billing approach.
5. Contact Kedrion Biopharma's patient access program. Pharmaceutical manufacturers of newly approved specialty biologics typically operate patient assistance and hub services to help navigate coverage and billing during the early launch period. Ask your doctor's office or infusion center whether a Kedrion access program is available.
Ellen can help you build your appeal. Start here
Frequently Asked Questions
Is Qivigy interchangeable with other IVIG products?
No. IVIG products are not interchangeable the way generic small-molecule drugs are. Each product is derived from pooled human plasma using different fractionation and stabilization processes, resulting in differences in concentration, stabilizer ingredients, infusion rate, and tolerability profiles. Substituting one IVIG product for another without clinical oversight is not appropriate. If your insurer asks why you cannot simply switch to a formulary-preferred IVIG, your physician's letter of medical necessity should address this directly.
What if my plan denies Qivigy and requires me to try a different IVIG first?
This is a step therapy denial. You have the right to appeal and to request an exception based on clinical necessity. In many states, step therapy exception laws require insurers to grant exceptions when a physician certifies that the step therapy protocol is not appropriate for a specific patient, when the required alternative has been tried and failed, or when the required alternative is contraindicated. Check your state's step therapy protections through your state insurance department.
How long does the J-code assignment process take for Medicare Part B billing?
CMS accepts HCPCS code applications on a rolling basis and publishes new codes twice yearly (January and July). A product approved by the FDA in late 2025 or early 2026 could receive a permanent J-code in the July 2026 update if the manufacturer applied promptly, or later if the application cycle was missed. During the interim period, billing under miscellaneous codes is possible but may require additional documentation and manual review by the Medicare contractor.